Arezoo Mohamadifar
Overview
Explore the profile of Arezoo Mohamadifar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
26
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Firuzi A, Shekarchizadeh M, Yadollahi M, Mohamadifar A, Ferasati E, Shekarchizadeh-Esfahani M
ARYA Atheroscler
. 2024 Jun;
19(3):18-24.
PMID: 38881583
Introduction: A well-known and fatal complication of myocardial infarction (MI) is post-infarction ventricular septal rupture (VSR). The benefits and risks associated with coronary angiography and subsequent coronary artery bypass grafting...
2.
Serati A, Keshmiri M, Shafaghi S, Mohammad M, Kashani B, Naghashzadeh F, et al.
Crit Pathw Cardiol
. 2023 May;
22(2):60-64.
PMID: 37220659
Background: The coronavirus 2019 (COVID-19) has affected the lives of many people worldwide. Patients with chronic underlying morbidities are vulnerable to get the severe form of the infection. The goal...
3.
Ranjbar M, Amin A, Amin A, Pouraliakbar H, Mohamadifar A
ESC Heart Fail
. 2023 May;
10(4):2702-2706.
PMID: 37216928
We are presenting a 35-year-old woman with past medical history of disseminated leiomyomatosis who presented with heart failure symptoms and was found to have post-capillary pulmonary hypertension and high cardiac...
4.
Hajimoradi M, Kashani B, Dastan F, Aghdasi S, Abedini A, Naghashzadeh F, et al.
Front Pharmacol
. 2023 Feb;
13:1107198.
PMID: 36733376
Remdesivir is effective against SARS-Cov-2 with little evidence of its adverse effect on the cardiac system. The aim of the present study is investigating the incidence of bradycardia in COVID-19...
5.
Naghashzadeh F, Shafaghi S, Dorudinia A, Naji S, Marjani M, Amin A, et al.
ESC Heart Fail
. 2022 Feb;
9(2):1483-1486.
PMID: 35106967
SARS-CoV-2 vaccines provide a safe solution with a major impact on reducing the spread of the virus and mild side effects. Research has shown rare cases of myocarditis after mRNA...
6.
Eshaghkhani Y, Mohamadifar A, Asadollahi M, Taghizadeh M, Karamzade A, Saberi M, et al.
Rep Biochem Mol Biol
. 2021 Oct;
10(2):280-287.
PMID: 34604417
Background: Dilated cardiomyopathy (DCM) is a progressive heart condition characterized by left ventricular chamber enlargement associated with systolic heart failure and prolonged action potential duration. Genetic variations in genes that...
7.
Amin A, Mohamadifar A, Keshmiri M, Ghadrdoost B, Taghavi S, Naderi N
J Crit Care
. 2016 Dec;
38:324-327.
PMID: 27988069
Background: Predicting prognosis is a cornerstone in management of pulmonary arterial hypertension. Hemodynamic parameters are among the robust indicators of right ventricular function and prognosis. In this study we have...
8.
Amin A, Mohamadifar A, Taghavi S, Naderi N, Sadeghi H
Res Cardiovasc Med
. 2015 Oct;
4(3):e26487.
PMID: 26436071
Background: Endothelin-receptor-antagonist, bosentan, has been found to improve the functional capacity and cardiopulmonary hemodynamics in Pulmonary Arterial Hypertension (PAH). Clinical trials have shown the preferable dosage of 125 mg, twice...